Results 211 to 220 of about 20,292 (247)

Patient and Cardiologist Perspectives on the Treatment of Patients With Concomitant ASCVD and Obesity

Journal of Patient Experience
Atherosclerotic cardiovascular disease (ASCVD) and obesity pose challenges to patients, healthcare professionals (HCPs), and health systems. The aim of this study was to understand the journey of patients with ASCVD and obesity, their caregivers, and ...
Pam R Taub, Michael G Knight, Lyn Behnke   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting Lp(a) to reduce ASCVD risk

Nature Reviews Cardiology, 2020
In a prespecified secondary analysis of the ACCELERATE trial, Puri and colleagues report a stepwise relationship between lipoprotein(a) levels and risk of major adverse cardiac events in patients with high-sensitivity C-reactive protein levels ≥2 mg/l.
openaire   +2 more sources

Renin angiotensin system and ASCVD

Current Opinion in Cardiology, 2000
The renin angiotensin system was first described over 100 years ago and is still the focus of intense clinical and basic science investigation. The renin angiotensin system was demonstrated to play a major pathogenetic role in hypertension. The development of inhibitors of angiotensin-converting enzyme and specific receptor blockers for angiotensin-II ...
openaire   +2 more sources

Detecting and Managing ASCVD in Women: A Focus on Statins

The Journal of Family Practice, 2022
At the end of the activity, participants will be able to:Summarize important findings and trends involving women and atherosclerotic cardiovascular disease (ASCVD). Characterize the multiple cardiometabolic changes that occur during menopause and the associated ASCVD risk.
openaire   +2 more sources

HDL cholesterol and ASCVD risk stratification: A debate

Atherosclerosis, 2019
This debate is designed to review the usefulness of the cholesterol mass within high-density lipoproteins (HDL-C) to predict the risk of atherosclerotic cardiovascular disease (ASCVD). PRO: There is much current confusion regarding the role of high density lipoproteins (HDLs) in atherosclerotic cardiovascular disease (ASCVD). While it is an established
Philip Barter, Jacques Genest
openaire   +2 more sources

ASCVD- Should We Treat It or Eradicate?

Research International Journal of Cardiology and Cardiovascular Medicine, 2023
Editorial Note Atherosclerotic cardiovascular disease (ASCVD) is a leading global health concern, signiϐicantly contributing to acute cardiovascular events such as myocardial infarction and ischemic stroke. Research consistently links elevated levels of low-density lipoprotein cholesterol (LDL-C) to ASCVD.
openaire   +1 more source

Burden of ASCVD in England

Atherosclerosis, 2022
D. Seshagiri, A. Durand, C.L. Morgan, R. Lahoz   +3 more
openaire   +1 more source

Treatment Thresholds and ASCVD Risk

Journal of the American College of Cardiology, 2021
openaire   +2 more sources

Aspirin dosing for secondary prevention in ASCVD

Nature Reviews Cardiology, 2021
openaire   +2 more sources

Minding the Gaps: Projecting the Consequences of Altering ASCVD Risk Thresholds on Type 2 Diabetes and ASCVD

2019
While the cardioprotective effect of statins are undeniable, experimental and observational research has suggested the potential for increased type 2 diabetes (T2D) risk. However, few studies have directly compared statin-associated benefits and harms or examined heterogeneity by population subgroups or assumed treatment effect.
openaire   +1 more source